Day 1 Stream 1 – Peptide Research, Chemistry, and Analytical Technologies

- New methods for peptide purification and characterisation
- Peptide optimisation
- Overcoming peptide challenges: stability, and bioavailability
- Macroyclic peptides and their applications in drug targeting
- Computer-aided peptide drug design

Day 1 Stream 2 – Peptide Therapeutics

- Updates from preclinical development
- Case studies from the areas of:
  - Metabolic disorders including diabetes
  - Oncology
  - Personalised medicine
  - Antimicrobial peptides
  - Immuno-therapy
- Peptide-based vaccines
- New peptides for novel disease treatments: case studies
- Peptidomimetics

Day 2 – Peptide Discovery, Manufacturing and Delivery

- Platforms for the discovery & development of peptides
- Advances in peptide synthesis technologies, strategies, novel methods
- Updates in cyclic peptides
- Peptide manufacturing and engineering
- Targeted delivery and peptide drug conjugates
- Safety assessment for peptides
- Peptides as biomaterials

Benefits to Attending

✓ **Hear from and meet with the key innovators in peptides.** Attendees include: Executive Director, Amgen; Director, Merck, Director, Pfizer; Associate Director, Eli Lilly; Senior Vice President and Chief Scientific Officer, Zealand Pharma

✓ **Discover advances in peptide research and analytical technologies.** From updates in peptide purification and peptide characterisation, to improving peptide properties, this stream will enable thought-provoking discussions with leading experts and opinion leaders

✓ **Discuss the latest innovations in peptide therapeutics.** Case studies will include the areas of metabolic and infectious diseases, personalised medicine, and novel therapeutic areas

✓ **Learn more about peptide discovery, manufacturing and delivery.** Gain unprecedented knowledge on novel discovery platforms, updates in cyclic peptides and advances in peptide synthesis

✓ **A high-quality programme devised with the help of our esteemed advisory board.** Presentations will cover peptide drug conjugates, peptide-based vaccines and peptidomimetics

Complimentary Live Webinars

- From Discovery To Phase 3 – A Zealand Perspective
- Macrocycle Medicinal Chemistry Optimization – Conformation Matters (Polyphor)

Register for free today

2018 Speakers Include:

Frank Thielmann    Michal Bassani-Sternberg    Jesse Dong
Novartis          CHUV & Ludwig Institute       Neon Therapeutics
for Cancer Research

Meet Senior Decision Makers

450 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

Peptide Analysis    Peptide Synthesis
Peptide Characterisation    Peptide Screening
Peptide Research    Therapeutic Discovery
Peptide Formulation    NBE Discovery
Peptide Synthesis    Medicinal Chemistry

Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Peptide Synthesis    Custom Peptide Synthesis
Peptide Arrays    Library Generation
Solid-phase Synthesis    Peptide Manufacturing
Peptide Labelling    Peptide Chemistry
Peptide Mapping    Peptide Screening
Peptide Engineering    Peptide Purification

For booking details & registration fees please refer to the last page or visit:

http://www.peptides-congress.com/marketing
2018 Confirmed Speakers Include:
- Les Miranda, Executive Director Research, Amgen
- Marian Gindy, Director Sterile Formulation Sciences, Merck
- Alan Mathiowitz, Director, Pfizer
- Todd Page, Director of Toxicology, Eli Lilly
- Vivian Lindo, Associate Director Product Characterisation, MedImmune
- Natia Tsomai, Associate Director, Ipsen
- Frank Thielmann, PMO and Operational Excellence Platform Leader, Novartis
- Stephen Buckley, Head of Discovery ADME, Novo Nordisk
- Mathias Schaffrath, Group Head Chromatography, Sanofi
- Lukas Leder, Lab Head Peptide Discovery Platform, Novartis
- Claudio Mapelli, Principal Scientist, Merck
- William Drury, Associate Principal Scientist, AstraZeneca
- Mohamed ElSayed, Senior Research Advisor & Program Leader, Eli Lilly
- Andreas Evers, Senior Scientist, Sanofi
- Elizabeth Pierson, Senior Scientist, Merck
- Thomas De Vijlder, Senior Scientist, Janssen
- Ying-Kai Wang, Senior Research Investigator II, Bristol Myers Squibb
- Magnus Jaderberg, Chief Medical Officer, Targovax
- Andy Parker, Senior Vice President and Chief Scientific Officer, Zealand Pharma
- Jesse Dong, Vice President Peptide Chemistry, Neon Therapeutics
- Daniel Obrecht, Chief Scientific Officer, Polyphor
- Mette Svendgaard, Director Pharmaceutical Development, Zealand Pharma
- Marc Thommen, Head of Chemistry, Polyphor
- Lihong Chen, Discovery Biology Team Leader, Bicycle Therapeutics Ltd
- Cedric Fiez-Vandal, Senior Scientist, Heptares Therapeutics
- Johannes Urban, Senior Scientist Technology Development, Morphosys
- David Craik, Professor & Group Leader, Chemistry and Structural Biology, University of Queensland
- Michal Bassani-Sternberg, Head of Immunopeptidomics Unit, Department of Oncology, University Hospital of Lausanne (CHUV), Switzerland and the Ludwig Institute for Cancer Research
- Steven Ballet, Professor, Free University Brussels
- Mark Howarth, Associate Professor, University of Oxford

2018 Co-located Peptides, Biosimilars & Biobetters and Proteins & Antibodies Congress Sponsors Include:

Previous Peptides Congress Sponsor And Delegate Testimonials Include:

“The agenda was put together impressively with a great attendance. The quality and numbers at the event are growing.”

Director, Business Development Europe, Polypeptide

“We had a great conference. The organisation was super, great opportunities to get our message across and a very pleasing response. Thank you to everyone involved.”

Marketing Manager, Horiba

“I liked the quality of presentations given at the conference. Also, the time during the poster presentation sessions was great to have discussions with other attending delegates.”

Head of Core Support, Sanofi R&D

“The organisation of the event was perfect, with excellent networking opportunities. The talks over both days were interesting and of high relevance for the field.”

Principal Scientist, Novartis

If you’re on Twitter, make sure to follow us @PeptideCongress and join the Congress conversation on #Pep18

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30 – 08.20</td>
<td>Registration</td>
</tr>
<tr>
<td>08.20 – 08.25</td>
<td>Oxford Global’s Welcome Address</td>
</tr>
<tr>
<td>08.25 – 08.30</td>
<td>Chairperson’s Opening Address</td>
</tr>
</tbody>
</table>
| 08.30 – 09.00| Co-Located Keynote Address: Advanced Protein Technologies To Support Discovery Reagents For Early Stage Biologics Program  
Ai Ching Lim, Director, Research, Amgen |
|              | Peptide Research, Chemistry And Analytical Technologies               |
| 09.00 – 09.30| Stream Keynote Address: New And Evolving Techniques For The Characterization Of Peptides  
Marian Gindy, Director Sterile Formulation Sciences, Merck |
|              | Stream Keynote Address: Peptide Therapeutics: Updates In Targeting Undruggable Spaces  
Natia Tsomaia, Associate Director, Ipsen |
| 09.30 – 10.00| Solution Provider Presentation                                       |
|              | Solution Provider Presentation                                        |
| 10.00 – 11.20| Morning Coffee & Refreshments, One to One Meetings x 3, Poster Presentation Sessions |
| 11.20 – 11.50| Structure And Dynamics Of Orally Bioavailable Peptides              |
|              | Pre-Clinical Therapeutic Discovery                                   |
|              | Les Miranda, Executive Director Research, Amgen                      |
| 11.50 – 12.20| Understanding Mechanisms Of Peptide Stability Enhancement           |
|              | Peptides In The Biopharmaceutical Industry Today And Tomorrow        |
|              | Frank Thielmann, PMO and Operational Excellence Platform Leader, Novartis |
| 12.20 – 12.50| Solution Provider Presentation                                       |
|              | Solution Provider Presentation                                        |
| 12.50 – 13.50| Lunch, Poster Presentation Sessions                                 |
| 13.50 – 14.20| Method Development And Purification Of Synthetic Peptides           |
|              | From Discovery To Phase 3 – A Zealand Perspective                   |
|              | Andy Parker, Senior Vice President and Chief Scientific Officer, Zealand Pharma |

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Panelist</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.20 – 14.50</td>
<td>Determination Of pH-Induced Oligomerization Of A Lipidated Peptide By Ion Mobility Spectrometry – Mass Spectrometry (IMS-MS)</td>
<td>Elizabeth Pierson, Senior Scientist, Merck</td>
</tr>
</tbody>
</table>
|          | • IMS-MS more definitively measures the dominant oligomer numbers of a peptide, even in a formulation-like environment  
|          | • Measurements reveal that a distribution of oligomers exists  
|          | • Drift times and rotationally-averaged collision cross sections can provide information on peptide structure and structural stability |                                           |
| 14.50 – 15.20 | Solution Provider Presentation | For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |
| 15.20 – 16.20 | Afternoon Coffee & Refreshments, One to One Meetings x3, Poster Presentation Sessions |                                           |
| 16.20 – 16.50 | Multi-Dimensional Peptide Optimization By In Silico Modeling And Efficient Experimental Profiling | Andreas Evers, Senior Scientist, Sanofi |
|          | In parallel to activity optimization at the target receptor(s), we consider physico-chemical and metabolic stability as early optimization parameter for the design of new peptides. For this purpose, orthogonal experimental methods and different in silico approaches – considering also 3D structural information if available - are continuously applied in an iterative manner. Examples will demonstrate how experimental methods and structural & in silico methods were not only used for (retrospective) compound assessment, but prospectively used as explicit parameter in multi-dimensional optimization. |                                           |
| 16.50 – 17.20 | Chemical And Physical Characterization Of Peptides In Research | Mette Svendgaard, Director Pharmaceutical Development, Zealand Pharma |
|          | Discovery Of Novel Outer-Membrane Protein Targeting Antibiotics (OMPTA) Against MDR Gram-Negative ESKAPE Pathogens | Daniel Obrecht, Chief Scientific Officer Polyphor |
|          | • There is a high medical need for new antibiotics with novel mechanism of action (MoA) against MDR/XDR Gram-negative ESKAPE pathogens |                                           |
|          | • Polyphor has discovered a novel class of antibiotics targeting specifically outer-membrane proteins of Gram-negative pathogens (OMPTA class) |                                           |
|          | • Murepavadin is a Pseudomonas-specific antibiotic entering Phase III clinical trials in 2018 is and the first member the OMPTA class |                                           |
|          | • Based on the novel MoA of Murepavadin Polyphor discovered a novel series of antibiotics with potent broad-spectrum Gram-negative activity overcoming also colistin-resistant pathogens |                                           |
|          | Development Of Personalized Cancer Vaccine NEO-PV-01 | Jesse Dong, Vice President Peptide Chemistry, Neon Therapeutics |
|          | • Neon Therapeutics is pursuing an exciting clinical development program of a personalized neoantigen vaccine, NEO-PV-01 |                                           |
|          | • Neoantigens arise as a result of somatic mutations during the development and progression of tumors, which are inherently non-self and are seen as foreign by the immune system |                                           |
|          | • NEO-PV-01 targets neoantigens unlocking the immune system to attack tumors |                                           |
|          | Update On RAS Mutation Specific Vaccine TG01 | Magnus Jaderberg, Chief Medical Officer, Targovax |
|          | • Why have so many peptide vaccines failed?  
|          | • What made Targovax focus on RAS mutations and pancreas cancer?  
<p>|          | • Will peptide vaccines combined with chemotherapy become standard of care in the future? |                                           |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.20 – 17.50</td>
<td>Macrocycles – Medicinal Chemistry Optimization Of Innovative Chemical Matter To Address Challenging Biological Targets</td>
<td>Marc Thommen, Head of Chemistry, Polyphor</td>
</tr>
<tr>
<td>17.50 – 18.20</td>
<td>Analytical Strategies To Characterize Peptide Deamidation</td>
<td>Thomas De Vijlder, Senior Scientist, Janssen</td>
</tr>
<tr>
<td>18.20 – 18.50</td>
<td>Crystal Structure Of A Family B GPCR Bound To A Peptide Agonist Ligand</td>
<td>Cedric Fiez-Vandal, Senior Scientist, Heptares Therapeutics</td>
</tr>
<tr>
<td>18.50</td>
<td>Think Tank Round Table Discussions And Networking Drinks - End of Day One</td>
<td></td>
</tr>
</tbody>
</table>

**Peptide Research, Chemistry And Analytical Technologies**

- **Macrocycle chemical matter** lies mostly beyond the "Lipinski rules space" and yet it provides innovative solutions for challenging (and hitherto "non-druggable") biological targets and target product profiles (in particular oral TPP’s) combining and complementing advantageous features of the two established drug classes “small molecules” and “biopharmaceuticals”. The talk emphasizes the medicinal chemistry optimization of both - peptidic and non-peptidic.

- **Analytical Strategies To Characterize Peptide Deamidation**
  - Challenges associated with the use of opioids in the alleviation of moderate to severe pains
  - Strategies to overcome side-effects
  - Design and biological evaluation of multiple opioid compounds
  - Peptide hydrogels

- **Crystal Structure Of A Family B GPCR Bound To A Peptide Agonist Ligand**
  - The X-ray structure of an agonist-bound full-length Family B GPCR unveils the remarkably complex network of interactions between peptide ligand and receptor protein
  - This structure increases our understanding of the mechanism of activation of the class B secretin group of GPCRs
  - Structure-based methods can be applied to the design of optimised peptide therapeutics

**Peptide Therapeutics**

- **Mass-Spectrometry Based Immunopeptidomics For Personalized Cancer Immunotherapy**
  - Biochemical extraction of HLA binding peptides form tumour tissues
  - Advanced mass-spectrometry analyses for identification and validation of HLA binding peptides
  - Immunopeptidomics in combination with genomics for identification of clinically relevant neo-antigens
  - Prioritization of tumour antigens for vaccination

- **Engineering (Hybrid) Peptidomimetics For Improved Pain Treatments**
  - Challenges associated with the use of opioids in the alleviation of moderate to severe pains
  - Strategies to overcome side-effects
  - Design and biological evaluation of multiple opioid compounds
  - Peptide hydrogels

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Role</th>
<th>Presentation Title</th>
</tr>
</thead>
</table>
| 08.30 – 09.00 | Keynote Address: Non-Clinical Safety Assessment Considerations For The Nonclinical Safety Assessment Of Peptides  | Todd Page, Director of Toxicology, Eli Lilly | Differences from mAb Safety Assessment  
High Dose Selection  
Species Selection  
Challenges associated with alternative/oral routes of delivery |
| 09.00 – 09.30 | Peptide Discovery, Manufacturing And Delivery  
Drug Delivery Of Peptides  
Stephen Buckley, Head of Discovery ADME, Novo Nordisk | Stephen Buckley, Head of Discovery ADME, Novo Nordisk | Non-Clinical Safety Assessment Considerations For The Nonclinical Safety Assessment Of Peptides  
Differences from mAb Safety Assessment  
High Dose Selection  
Species Selection  
Challenges associated with alternative/oral routes of delivery |
| 09.30 – 10.00 | Solution Provider Presentation  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |  
| 10.00 – 11.00 | Morning Coffee & Refreshments, One to One Meetings x 3, Poster Presentation Sessions |  
| 11.00 – 11.30 | The Peptide Discovery Platform: Overview, Application In Projects And Future Directions  
Lukas Leder, Lab Head Peptide Discovery Platform, Novartis | Lukas Leder, Lab Head Peptide Discovery Platform, Novartis | Overview of the mRNA display based technique to identify high affinity binding peptides  
How can the platform support drug discovery projects?  
What will be further developments and innovations to generate more impact? |
| 11.30 – 12.00 | Solution Provider Presentation  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |  
| 12.00 – 12.30 | Protein Synthesis At Medicinal Chemistry Speed: Linear And Convergent Routes For The Synthesis Of Small Proteins  
Claudio Mapelli, Principal Scientist, Merck | Claudio Mapelli, Principal Scientist, Merck | Targeted Delivery Of Therapeutic Oligonucleotides To Pancreatic Beta Cells  
Conjugation of GLP1 analogs to therapeutic antisense oligonucleotides (ASO) allow for selective delivery to pancreatic beta cells, a previously inaccessible cell type  
Delivery to the pancreas is selective and robust, even a doses that do not cause ASO accumulation in the liver and kidneys  
Basic pharmacology and ligand structure activity relationships underpinning the delivery system have been investigated, and will be discussed |
| 12.30 – 13.30 | Lunch, Poster Presentation Sessions |  
| 13.30 – 14.00 | Targeted Delivery Of Therapeutic Oligonucleotides To Pancreatic Beta Cells  
William Drury, Associate Principal Scientist, AstraZeneca | William Drury, Associate Principal Scientist, AstraZeneca | Targeted Delivery Of Therapeutic Oligonucleotides To Pancreatic Beta Cells  
Conjugation of GLP1 analogs to therapeutic antisense oligonucleotides (ASO) allow for selective delivery to pancreatic beta cells, a previously inaccessible cell type  
Delivery to the pancreas is selective and robust, even a doses that do not cause ASO accumulation in the liver and kidneys  
Basic pharmacology and ligand structure activity relationships underpinning the delivery system have been investigated, and will be discussed |
| 14.00 – 14.30 | Cyclic Peptide Discovery From Plants And Animals  
David Craik, Professor & Group Leader, Chemistry and Structural Biology, University of Queensland | David Craik, Professor & Group Leader, Chemistry and Structural Biology, University of Queensland | Cyclic Peptide Discovery From Plants And Animals  
Cyclic peptides are typically very stable and have advantages over their linear counterparts  
Cyclotides are a class of cyclic peptide that is particularly amenable to use as a "grafting" template in drug design  
Some cyclic peptides are able to penetrate cells to attack intracellular targets |
| 14.30 – 15.00 | Platforms For Peptide Drug Discovery  
Ying-Kai Wang, Senior Research Investigator II, Bristol Myers Squibb | Ying-Kai Wang, Senior Research Investigator II, Bristol Myers Squibb | Platforms For Peptide Drug Discovery |
| 15.00 – 15.30 | Afternoon Coffee & Refreshments, One to One Meetings x 3, Poster Presentation Sessions |  
| 15.30 – 16.00 | Challenges And Opportunities In Oral Delivery Of Therapeutic Peptides  
Mohamed ElSayed, Senior Research Advisor & Program Leader, Eli Lilly | Mohamed ElSayed, Senior Research Advisor & Program Leader, Eli Lilly | Challenges And Opportunities In Oral Delivery Of Therapeutic Peptides  
The presentation will focus on describing the barriers to oral absorption of peptides (e.g. size, molecular weight, proteolytic instability in the GIT) and current strategies used to enhance oral absorption of peptides (e.g. enteric coating, use of permeation enhancers, peptidase inhibitors). |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 16.30</td>
<td><strong>Bicycles®, Constrained Bicyclic Peptides – A New Therapeutic Modality</strong></td>
</tr>
<tr>
<td></td>
<td>• The Bicycle opportunity</td>
</tr>
<tr>
<td></td>
<td>• Applications of the technology</td>
</tr>
<tr>
<td></td>
<td>• Case study</td>
</tr>
<tr>
<td></td>
<td><strong>Liu Hong Chen, Discovery Biology Team Leader, Bicycle Therapeutics Ltd</strong></td>
</tr>
<tr>
<td>16.30 – 17.00</td>
<td><strong>Engineering Of Artificial Lanthipeptides</strong></td>
</tr>
<tr>
<td></td>
<td>• MOR107, a selective lanthipeptide agonist of the angiotensin II receptor</td>
</tr>
<tr>
<td></td>
<td>• De novo selection of functional lanthipeptides by phage display</td>
</tr>
<tr>
<td></td>
<td><strong>Johannes Urban, Senior Scientist Technology Development, Morphosys</strong></td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td><strong>Spy And Snoop Peptide Superglues For Assembly Of Vaccines, Enzymes And Biomaterials</strong></td>
</tr>
<tr>
<td></td>
<td>• SpyTag and SnoopTag are superglues for unbreakable peptide-mediated nano-assembly</td>
</tr>
<tr>
<td></td>
<td>• Peptide-decorated virus-like particles should accelerate vaccine development for malaria and cancer</td>
</tr>
<tr>
<td></td>
<td>• Molecular team-building enables precise control of cell signalling in cancer cell death</td>
</tr>
<tr>
<td></td>
<td><strong>Mark Howarth, Associate Professor, University of Oxford</strong></td>
</tr>
<tr>
<td>17.30</td>
<td><strong>End of Conference</strong></td>
</tr>
</tbody>
</table>

For more information please contact marketing@oxfordglobal.co.uk
Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates.

Title: _____________________ Forename: __________ Surname: _____________________
Job Title: ____________________
Company/Organisation: __________________________
Email: ____________________________
Address: __________________________________________
Postcode: ____________________________ Country: ____________________________
Direct Telephone: ________________ Direct Fax: __________________
Mobile: ____________________________ Switchboard: ________________
Signature: ____________________________ Date: ____________________________

Registration Fees

I would like to attend: (Please tick as appropriate)

Industry Delegates (Biopharma, Pharma or Biotech Companies)

☐ Congress £799 plus VAT
☐ Day 1 £499 plus VAT
☐ Day 2

Academic Delegates

☐ Congress £499 plus VAT
☐ Day 1 £299 plus VAT
☐ Day 2

Vendor Delegates (CROs, Consultants, Technology and Service Providers)

☐ Congress Only £1750 plus VAT
☐ Day 1 £799 plus VAT
☐ Day 2

☐ Poster Presentation £250 plus VAT

☐ PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company’s promotional literature to all conference attendees £999 plus VAT

Documentation

I cannot attend but would like to purchase access to the following:

☐ Access to the online conference presentations £499 plus VAT
☐ Conference presentations - paper copy £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

How to Pay (choose one of the following payment options)

Number of delegates:

☐ Industry del(s) ☐ Academic dels(s) ☐ Vendor dels(s)

☐ Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

□ CREDIT CARD: ☐ Visa ☐ MasterCard ☐ Maestro ☐ Amex

Credit Card Number: ____________________________
Valid from: ________________ Expiry Date: ________________
Security code: ________________

☐ PLEASE INVOICE ME:

Invoice Address (if different from above)

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

Delegate Booking Fee

The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.

Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Poster Presentations

Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

Cancellation and Curtailment

Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior 35% cancellation fee / 65% refund
Between 6 and 3 months prior 75% cancellation fee / 25% refund
Less than 3 months prior to the event Full cancellation fee / No refund

Data Protection

The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein.

Miscellaneous

This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

☐ I agree to the above Terms and Conditions

*Please note there is a £50 plus VAT handling charge for payment via invoice
*All card payments will be subject to a 3% bank charge or 4% AMEX charge

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk